Growth Equity
Westcore MIDCO Growth Fund

Ticker: WTMGX | CUSIP: 957904717 | Style: Mid-Cap Growth | Inception Date: 8/1/1986
Share Class:
Fund:


Manager Commentary as of 6/30/2010

  • We are pleased that the Westcore MIDCO Growth Fund outperformed its benchmark the Russell Midcap Growth Index in the second quarter with a return of -9.41% versus the -10.20% return of the index.

     
  • Equity markets struggled in the second quarter as investors digested the large gains off the March 2009 lows.  Sovereign debt crises, growing state and federal budget deficits, a major oil spill in the Gulf of Mexico and an apparent economic soft patch all contributed to the weak performance.  Despite what appears to be moderation of economic growth, we continue to find innovative companies that we believe can succeed in a slower growth environment. 

 

  • In the second quarter of 2010, the top three contributing sectors relative to the benchmark were information technology, energy and consumer staples. For the second quarter in a row, our best performing stock was Netflix Inc., in the consumer discretionary sector.  Netflix’s prolific “Watch Instantly” streaming service continues to drive strong margins and subscriber growth.  Akamai Technologies Inc. is a provider of services for accelerating and improving the delivery of Internet content and applications.  This information technology sector holding outperformed as it continued to benefit from increased demand for video and applications delivered over the Internet.   

 

  • The Fund’s three largest detractors from performance relative to the benchmark in the quarter were the financials, health care and materials sectors.  Financials sector holding Waddell & Reed Financial Inc. was the Fund’s worst performing stock in the quarter.  This investment management company suffered from poor performance in its largest investment strategy which led us to sell the position during the quarter.  In the health care sector, King Pharmaceuticals Inc. underperformed as concerns arose over the growth of this pharmaceutical manufacturer’s existing product line and management’s ability to develop the company’s new product portfolio.  We believe recent pressure has substantially undervalued the company and see a favorable opportunity for the company’s new product line.  We are confident in management’s ability and see a delay in the development of this product line as temporary.     

 

  • Of note, as the quarter progressed, we found valuations increasingly attractive in the energy sector.  The BP oil spill drove significant stock weakness across the sector, and we used this as an opportunity to add to existing holdings and initiate new positions in attractive companies.  As we enter the second half of 2010, we see attractive growth prospects in the energy sector.     

 

  • We believe our in-depth research focus at the company level helps us identify good growth opportunities despite a potentially slower growth environment.  As of June 30, 2010, the Fund’s primary overweight positions were in the information technology and industrials sectors and its largest underweights were in the consumer staples and consumer discretionary sectors. 

  • As always, we thank you for your continued investment.

 

The performance data quoted represents past performance and does not guarantee future results. Investment return and principal value will vary, and shares, when redeemed, may be worth more or less than their original cost. To obtain current performance as of the most recent month-end, please call 800.392.CORE (2673) or visit the Performance tab.

 

Stock Performance (3 months ended 6/30/2010)

 

Top 5 Stocks

Average

Weight

Contribution

To Return

Netflix Inc.

1.46%

0.56%

Akamai Technologies Inc.

2.03

0.41

Lincare Holdings Inc.

2.14

0.16

Community Health Systems Inc.

0.41

0.15

Dolby Laboratories Inc.

1.97

0.09

 

 

Bottom 5 Stocks

Average

Weight

Contribution

To Return

T. Rowe Price Group Inc.

2.15%

-0.40%

Warnaco Group Inc.

1.68

-0.40

Robert Half International Inc.

1.35

-0.42

King Pharmaceuticals Inc.

1.09

-0.42

Waddell & Reed Financial Inc.

1.05

-0.43




The Top 5 and Bottom 5 performing stocks do not represent all of the securities purchased, sold or recommended by the Funds’ Adviser. The methodology used to construct this chart took into account the weighting of every holding in the Fund that contributed to the Fund’s performance during the measurement period. The contribution of each Fund holding was consistently determined by calculating the weight of each holding multiplied by the rate of return for that holding during the measurement period. To request a complete list of the contribution of each Fund holding to overall Fund performance, please call
800-392-CORE (2673) or visit the Performance tab.

The Manager Commentaries contain certain forward-looking statements about the factors that may affect the performance of the Funds in the future. These statements are based on Fund management’s predictions and expectations concerning certain future events and their expected impact on the Funds, such as performance of the economy as a whole and of specific industry sectors, changes in the levels of interest rates, the impact of developing world events, and other factors that may influence the future performance of the Funds. Management believes these forward-looking statements to be reasonable, although they are inherently uncertain and difficult to predict. Actual events may cause adjustments in portfolio management strategies from those currently expected to be employed.

All indices are unmanaged and investors cannot invest directly in an index. View index descriptions.

View glossary of terms.

View current performance.